Tergene Biotech gets recommendation from CDSCO subject expert committee for pneumococcal 15-valent vaccine https://ift.tt/hH0yiB2

The subject expert committee (SEC) at its meeting held on December 21, 2022, has recommended a grant of permission to Tergene to manufacture and market a 15-valent Pneumococcal Polysaccharide conjugate vaccine with three-dose schedule for administration into the pediatric age group of 6, 10 and 14 weeks, Aurobindo Pharma said in a regulatory filing.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/6ARMfW3